List of works - Michele Merli

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

scientific article published on 31 May 2017

A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!

scientific article published on 07 November 2019

Antiviral therapies for managing viral hepatitis in lymphoma patients.

scientific article

Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma

scientific article

Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry.

scientific article published in November 2010

Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection.

scientific article published on May 2009

Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients

scientific article published on 21 August 2008

Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia.

scientific article

Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network

scientific article published on 09 September 2019

Clinical predictors of outcome in MPN.

scientific article published on 28 August 2012

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

scientific article published on 11 February 2019

Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas

scientific article published on 14 December 2018

Direct-acting Antivirals in Hepatitis C Virus-positive Mantle Cell Lymphomas

scientific article published on 05 November 2020

Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas

scientific article

Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

scientific article published on 28 April 2020

Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma.

scientific article published in February 2011

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

scientific article

Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study

scientific article published on 10 July 2019

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study

scientific article published on 08 November 2018

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

scientific article published on 01 November 2019

Everolimus in diffuse large B-cell lymphomas

scientific article

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project

scientific article published on 21 September 2018

High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma

scientific article published on 03 August 2009

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

scientific article published on 01 November 2019

Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas

article

Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence.

scientific article published in September 2010

Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.

scientific article

Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.

scientific article published on 7 September 2016

Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection

scientific article published on 13 December 2019

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma

scientific article published on 21 April 2015

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma

scientific article published on 23 May 2017

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.

scientific article

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma

scientific article published on 3 August 2017

Looking for CALR mutations in familial myeloproliferative neoplasms.

scientific article published on 20 January 2014

Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma.

scientific article published on 3 July 2013

New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma

scientific article

Novel agents in indolent lymphomas.

scientific article

Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi

scientific article published on 22 November 2013

Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis

scientific article published on 13 October 2020

Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy

scientific article published on 24 June 2014

Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection

scientific article published on 11 June 2020

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS ⬇️

scientific article published on September 30, 2010

Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection.

scientific article published on 11 April 2011

Risk of second cancer in nongastric marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue: a population-based study from northern Italy

scientific article published on 01 January 2007

Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.

scientific article published on 6 January 2016

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

scientific article

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma

scientific article published on 31 January 2017

Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires.

scientific article published on 27 February 2009

Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi

scientific article published on 15 June 2020

The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms.

scientific article

The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection

scientific article published on 7 November 2014

The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.

scientific article

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death

scientific article published on 08 November 2018

Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients.

scientific article published on 11 January 2010

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

scientific article published on 5 April 2018

Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

scientific article published on 11 August 2020

List of works by Michele Merli

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!

Antiviral therapies for managing viral hepatitis in lymphoma patients.

Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma

Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry.

Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection.

Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients

Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia.

Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network

Clinical predictors of outcome in MPN.

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas

Direct-acting Antivirals in Hepatitis C Virus-positive Mantle Cell Lymphomas

Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas

Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma.

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

Everolimus in diffuse large B-cell lymphomas

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project

High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas

Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence.

Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.

Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.

Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma

Looking for CALR mutations in familial myeloproliferative neoplasms.

Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma.

New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma

Novel agents in indolent lymphomas.

Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi

Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis

Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy

Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS ⬇️

Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection.

Risk of second cancer in nongastric marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue: a population-based study from northern Italy

Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma

Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires.

Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi

The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms.

The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection

The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death

Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies